Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-064468
Filing Date
2025-05-06
Accepted
2025-05-06 16:10:28
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crsp-20250331.htm   iXBRL 10-Q 1844687
2 EX-31.1 crsp-ex31_1.htm EX-31.1 12768
3 EX-31.2 crsp-ex31_2.htm EX-31.2 12768
4 EX-32.1 crsp-ex32_1.htm EX-32.1 12049
5 GRAPHIC img170269123_0.jpg GRAPHIC 161430
  Complete submission text file 0000950170-25-064468.txt   8364861

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250331.xsd EX-101.SCH 962868
65 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250331_htm.xml XML 1636259
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37923 | Film No.: 25917351
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)